Coya Therapeutics (COYA) EBITDA (2022 - 2026)

Coya Therapeutics (COYA) has 5 years of EBITDA data on file, last reported at -$7.6 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA changed 0.48% year-over-year to -$7.6 million; the trailing twelve-month figure through Mar 2026 stood at -$22.5 million (down 15.81% YoY), and the FY2025 full-year result was -$22.6 million, down 30.76% from the prior year.
• EBITDA fell to -$7.6 million in Q1 2026, from -$6.0 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $1.8 million in Q4 2023 to a low of -$7.7 million in Q1 2025.
• A 5-year average of -$3.8 million and a median of -$3.4 million in 2022 frame the typical range for EBITDA.
• Across the five-year window, EBITDA surged 190.6% in 2023 and tumbled 324.79% in 2024, its largest moves.
• Tracing COYA's EBITDA over 5 years: stood at -$2.0 million in 2022, then surged by 190.6% to $1.8 million in 2023, then slumped by 324.79% to -$4.1 million in 2024, then plunged by 47.81% to -$6.0 million in 2025, then slipped by 26.68% to -$7.6 million in 2026.
• Business Quant data shows COYA's EBITDA at -$7.6 million in Q1 2026, -$6.0 million in Q4 2025, and -$2.4 million in Q3 2025.